Lucira Health falls on weak Q2 COVID test sales

Lucira Health

16/08/2022 17:28

** Shares of Lucira Health Inc  LHDX.O  slide 16.5% to $2.79
- set for biggest pct fall in nearly three months
    ** Reports Q2 net sales of $26.1 mln, below Refinitiv IBES
estimates of $30.1 mln, hit by low demand for its COVID-19 tests
 urn:newsml:reuters.com:*:nGNX8bYrzw 
    ** Including session's fall, stock down ~68% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))